Vol 74, No 4 (2024)
Research paper (original)
Published online: 2024-09-02

open access

Page views 124
Article views/downloads 44
Get Citation

Connect on Social Media

Connect on Social Media

Pattern of lung cancer recurrence after lung resection with bilateral lymph node dissection

Jakub Szadurski1, Łukasz Trybalski1, Jarosław Kużdżał2, Aleksander Galas3, Janusz Warmus1, Zbigniew Grochowski1, Mirosław Janczura2, Katarzyna Żanowska1, Piotr Kocoń2
Nowotwory. Journal of Oncology 2024;74(4):254-258.

Abstract

Introduction.  Several studies have shown the survival benefit of bilateral lymph node dissection as part of curative- -intent surgery for lung cancer. The pilot BML-1 study was the first randomized trial comparing bilateral with the standard (unilateral) systematic lymph node dissection.

Material and methods.  Patients with non-small cell lung cancer stage I–IIIA, who underwent anatomical lung resec­tion were randomised 1:1 to receive a bilateral or standard, unilateral lymphadenectomy. Data regarding the type of recurrence and time to recurrence were analysed.

Results.  The rate of locoregional recurrence in the bilateral lymphadenectomy and the standard lymphadenectomy were 2.7% and 5.3% and those of distant relapse were 24.3% and 23.7% respectively (p = 0.99). The follow-up time was 87 months. The mean time from surgery to recurrence was 35.0 months and 22.8 months, respectively (p = 0.83).

Conclusions.  There is no firm evidence that bilateral mediastinal lymphadenectomy (BML) is associated with a re­currence pattern that is different than that following the systematic lymph node dissection (SLND). We found a trend towards lower incidence of local recurrence and longer time to recurrence in the BML group, but the differences were statistically not significant. A large randomised study is warranted to further analyse this matter.

Article available in PDF format

View PDF Download PDF file

References

  1. Kużdżał J, Trybalski Ł, Hauer Ł, et al. Influence of bilateral mediastinal lymph node dissection on survival in non-small cell lung cancer patients - Randomized study. Lung Cancer. 2021; 156: 140–146.
  2. Hata E, Hayakawa K, Miyamoto H, et al. Rationale for extended lymphadenectomy for lung cancer. Theor Surg. 1990; 5: 19–25.
  3. Sakao Y, Miyamoto H, Yamazaki A, et al. Prognostic Significance of Metastasis to the Highest Mediastinal Lymph Node in Nonsmall Cell Lung Cancer. Ann Thorac Surg. 2006; 81(1): 292–297.
  4. Hata E, Miyamoto H, Sakao Y. Investigation into mediastinal lymph node metastasis of lung cancer and rationale for decision of the extent of mediastinal dissection. Nihon Geka Gakkai Zasshi. 1997; 98(1): 8–15.
  5. Kawano R, Hata E, Ikeda S, et al. [Surgical treatment of N2 involved non-small cell lung cancer--the systematic extended lymph node dissection based on the regional lymphatic drainage]. Kyobu Geka. 1999; 52(11): 901–905.
  6. Brunelli A, Charloux A, Bolliger CT, et al. ERS/ESTS clinical guidelines on fitness for radical therapy in lung cancer patients (surgery and chemo-radiotherapy). Eur Respir J. 2009; 34(1): 17–41.
  7. Yamauchi Y, Muley T, Safi S, et al. The dynamic pattern of recurrence in curatively resected non-small cell lung cancer patients: Experiences at a single institution. Lung Cancer. 2015; 90(2): 224–229.
  8. Karacz CM, Yan J, Zhu H, et al. Timing, Sites, and Correlates of Lung Cancer Recurrence. Clin Lung Cancer. 2020; 21(2): 127–135.e3.
  9. Jeong WGi, Choi H, Chae KJu, et al. Prognosis and recurrence patterns in patients with early stage lung cancer: a multi-state model approach. Transl Lung Cancer Res. 2022; 11(7): 1279–1291.